Genetics Institute, Inc.

Wyeth

Medimmune Limited

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Other

Harvard College

Allied Corporation

Johns Hopkins University

Cambridge Antibody Technology Limited

The Government of the United States of America

Mary Collins

Matthew James Whitters

Clive R Wood

Debra D Donaldson

Beatriz M Carreno

Lori J Fitz

Tamlyn Neben

Deborah A Young

Gary S Gray

Denise M O'Hara

Maximiliano Vasquez

Geertruida Machteld Veldman

Samuel Goldman

Man Sung Co

Abbie Cheryl Celniker

Andrea Knight

Bonita Rup

Edward F Fritsch

Laura L Carter

Viia Valge-Archer

Caroline S Russell

Joseph P Dougherty

Deborah P Luxenberg

John Edward Andrews

Michael J Grusby

Marian S Ellwood

Joann Witek

Jason Jussif

Thomas A Wynn

Frances K Bennett

Steven E Diamond

Jon I Williams

Andrew James Williams

Michelle J Unger

Marsha Wills-Karp

Joseph G Brewen

Andrea Wurster

Monica G Chiaramonte

Naoya Tsurushita

Kenneth A Jacobs

Glenn R Larsen

Paul Robert Hinton

Katherine Jane Turner

Eugene L Brown

Marion T Kasaian

Ethan Shevach

Michael Chapman Byrne

Padmalatha S Reddy

Lesile D Lowe

Margery Ma

Kyri Dunussi

Leslie D Lowe

Vila Valge-Archer

Geoffrey Laurence Stephens

Rebecca Suzanne McHugh

Donna Morris

Joanne Witek

Laura K Carter

Frances Bennett

Caroline Russell

John Andrews

Lori Fitz

Matthew J Whitters

Michelle Ungar

Joann S Witek

Viia Valge-archer

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

Nucleic acids encoding antibodies against PD-1

The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e.g., the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e.g., the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i.e., the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e.g., the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).

Methods for treating and preventing fibrosis

Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.

[object Object]

Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.

Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding

The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2

The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.

Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies

The present invention is directed to methods for treating asthma.

Method and compositions for treating asthma

The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.

Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules

Methods of upmodulating adaptive immune response using anti-PD-1 antibodies

Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed. Methods of medical treatment using such molecules and antagonists of the IL-13/IL-13R interaction are also provided.

Cytokine receptor chain

Antibodies against human or mouse IL-21 receptor

Antibodies against PD-1

Methods and compositions for modulating T helper (Th) cell development and function

Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.

Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains

Growing community of inventors

Natick, MA, United States of America

Mary Collins